Jagsonpal Pharmaceuticals Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7obslwl25q4a2ulw00qe14ay.pdf

Key Takeaways


Organic Growth Engine

Manish Gupta: "We will not get into like Elagolix is going off patent and there will be a lot of companies launching that. We will stay away in those kinds of launches. All our products will be slightly differentiated and hardworking or products requiring hard work in doctor's chamber."

Yash Pharma Integration


Margin Trajectory

Manish Gupta: "But this is a journey. And you cannot reach the destination without going through this journey. So therefore, yes, if we are lucky and if we end up with the top end of our growth target, maybe our margin expansion will be 200 bps in the next couple of quarters or around that. But I know the reality because certain things work out and certain things do not work out when you are running strategy across 300 people in each division."

Capital Allocation & Balance Sheet

Manish Gupta: "But any inorganic acquisition has to fit both our strategy and also pricing criteria. Because a mistake there can be very expensive for the organization. So we are a disciplined buyer."

Portfolio & Therapeutic Mix


Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue growth12% to 14% top line growth on a stable basisBeyond FY25
Volume growth3% to 4% annuallyOngoing
Price growth3% to 5% annuallyOngoing
New product launches8 to 10 new products each year, roughly two per divisionAnnual
Gross margin improvement50 to 75 bps year on yearAnnual
Operating margin expansion120 bps to 150 bps year on year; up to 200 bps if top-end growth achievedNext couple of quarters
Cash balanceFairly close to ₹150 crores, give or take ₹1-2 croresFY25 year-end
Yash Pharma revenue share18% to 22% of overall organizationOngoing, barring new acquisition
Divatrone growth resumptionShould start reflecting in growthQ4 FY25 onwards
CFO onboardingWithin 60 days, within current financial year ending MarchFY25

Key Metrics

MetricQ3 FY25
Revenue₹74 crores, +57% YoY
Organic revenue growth27% YoY
Operating EBITDA (pre-ESOP)₹17 crores, +183% YoY
Operating margin (pre-ESOP)23.1%
Net profit₹11.5 crores, +190% YoY; net profit margin 15.5%
Exceptional income (Faridabad facility sale)~₹23 crores
YTD revenue₹210 crores, +27% YoY
YTD operating margin (pre-ESOP)22.9%, expanded 390 bps YoY
YTD net profit from operations₹31.6 crores, +67% YoY
Cash balance₹132 crores at end-December, up from ₹93 crores at end-September
Operating cash generation₹15–18 crores per quarter
Organic growth YTD8%
Volume growth (like-to-like)~one-third of the 8% organic growth
Yash Pharma revenue~₹14 crores per quarter, ~20% of total revenues
MR productivity~₹2.5 lakhs per month, sub-₹3 lakhs
MR strength~900 MRs
ESOP cost₹1.3 crores in Q3; run rate ₹1.7–1.8 crores per quarter for next 2 quarters
Gross margin improvement expectation50–75 bps YoY
Top-line growth guidance (stable basis)12–14% going forward
Margin expansion expectation120–150 bps YoY
New product launches planned8–10 per year, ~2 per division across 4 divisions
Gynae revenue share50% of total revenues
Ortho revenue share~20% of total revenues
Pedia and Derma revenue share12–15% each
Divatrone internal sales~one-third of levels 18 months ago; decline arrested, green shoots from December